PREBIOTIC EFFECT OF BIMUNO® GOS
Embracing the ever-evolving landscape of minimalist skincare trends, CTC Vietnam takes pride in unveiling a range of versatile skincare product formulas crafted from innovative, 100% natural ingredients. This announcement positions CTC Vietnam at the forefront of the skincare industry, providing consumers with cutting-edge solutions that prioritize simplicity and effectiveness.
Bimuno® GOS prebiotic demonstrated bifidogenic effects from 7 days at optimal dosage from 1.37g per day, as well as exhibiting a superior bifidogenic effect to that of another GOS, highlighting the potential role of Bimuno® GOS in the maintenance of a healthy gut microbiota.
Positive modulatory effects of Bimuno® GOS on the gut microbiota have been observed in healthy individuals including the elderly, overweight individuals at risk of metabolic syndrome, individuals with functional gut disorders and Irritable Bowel Syndrome, Ulcerative Colitis patients with mild symptom severity and children with Autism, suggesting Bimuno® GOS may help support a healthy gut microbiota in various populations, including those with gastrointestinal conditions.
References:
(1) Depeint F, Tzortzis G, Vulevic J, I’anson K, Gibson GR. 2008. Prebiotic evaluation of a novel galactooligosaccharide mixture produced by the enzymatic activity of Bifidobacterium bifidum NCIMB 41171, in healthy humans: a randomized, double-blind, crossover, placebo-controlled intervention study. Am J Clin Nutr., 87(3):785-91. DOI:10.1093/ajcn/87.3.785.
(2) Vulevic J, Drakoularakou A, Yaqoob P, Tzortzis G, Gibson GR. 2008. Modulation of the fecal microflora profile and immune function by a novel trans-galactooligosaccharide mixture (B-GOS) in healthy elderly volunteers. Am J Clin Nutr. 88(5):1438-46. DOI:10.3945/ajcn.2008.26242.
(3) Vulevic J, Juric A, Walton GE, Claus SP, Tzortzis G, Toward RE, Gibson GR. 2015. Influence of galacto-oligosaccharide mixture (B-GOS) on gut microbiota, immune parameters and metabonomics in elderly persons. Br J Nutr. 114(4):586-95. DOI:10.1017/S0007114515001889.
(4) Vulevic J, Juric A, Tzortzis G, Gibson GR. 2013. A mixture of trans-galactooligosaccharides reduces markers of metabolic syndrome and modulates the fecal microbiota and immune function of overweight adults. J Nutr. 143(3):324-31. DOI:10.3945/ jn.112.166132.
(1) Depeint F, Tzortzis G, Vulevic J, I’anson K, Gibson GR. 2008. Prebiotic evaluation of a novel galactooligosaccharide mixture produced by the enzymatic activity of Bifidobacterium bifidum NCIMB 41171, in healthy humans: a randomized, double-blind, crossover, placebo-controlled intervention study. Am J Clin Nutr., 87(3):785-91. DOI:10.1093/ajcn/87.3.785.
(2) Vulevic J, Drakoularakou A, Yaqoob P, Tzortzis G, Gibson GR. 2008. Modulation of the fecal microflora profile and immune function by a novel trans-galactooligosaccharide mixture (B-GOS) in healthy elderly volunteers. Am J Clin Nutr. 88(5):1438-46. DOI:10.3945/ajcn.2008.26242.
(3) Vulevic J, Juric A, Walton GE, Claus SP, Tzortzis G, Toward RE, Gibson GR. 2015. Influence of galacto-oligosaccharide mixture (B-GOS) on gut microbiota, immune parameters and metabonomics in elderly persons. Br J Nutr. 114(4):586-95. DOI:10.1017/S0007114515001889.
(4) Vulevic J, Juric A, Tzortzis G, Gibson GR. 2013. A mixture of trans-galactooligosaccharides reduces markers of metabolic syndrome and modulates the fecal microbiota and immune function of overweight adults. J Nutr. 143(3):324-31. DOI:10.3945/ jn.112.166132.
(5) Huaman JW, Mego M, Manichanh C et al. 2018. Effects Of Prebiotics Vs A Diet Low In FODMAPs In Patients With Functional Gut Disorders. Gastroenterology. 155(4):1004-1007. DOI:10.1053/j. gastro.2018.06.045.
(6) Silk DB, Davis A, Vulevic J, Tzortzis G, Gibson GR. 2009. Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment Pharmacol Ther. 1;29(5):508-18. DOI:10.1111/j.1365- 2036.2008.03911.x.
(7) Wilson B, Eyice Ö, Koumoutsos I, Lomer MC, Irving PM, Lindsay JO, Whelan K. 2021. Prebiotic Galactooligosaccharide Supplementation in Adults with Ulcerative Colitis: Exploring the Impact on Peripheral Blood Gene Expression, Gut Microbiota, and Clinical Symptoms. Nutrients. 14;13(10):3598. DOI:10.3390/ nu13103598.
(8) Grimaldi R, Gibson GR, Vulevic J, Giallourou N, Castro-Mejía JL, et al. 2018. A prebiotic intervention study in children with autism spectrum disorders (ASDs). Microbiome. 6(1):133. DOI:10.1186/ s40168-018-0523-3.
(6) Silk DB, Davis A, Vulevic J, Tzortzis G, Gibson GR. 2009. Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment Pharmacol Ther. 1;29(5):508-18. DOI:10.1111/j.1365- 2036.2008.03911.x.
(7) Wilson B, Eyice Ö, Koumoutsos I, Lomer MC, Irving PM, Lindsay JO, Whelan K. 2021. Prebiotic Galactooligosaccharide Supplementation in Adults with Ulcerative Colitis: Exploring the Impact on Peripheral Blood Gene Expression, Gut Microbiota, and Clinical Symptoms. Nutrients. 14;13(10):3598. DOI:10.3390/ nu13103598.
(8) Grimaldi R, Gibson GR, Vulevic J, Giallourou N, Castro-Mejía JL, et al. 2018. A prebiotic intervention study in children with autism spectrum disorders (ASDs). Microbiome. 6(1):133. DOI:10.1186/ s40168-018-0523-3.